Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Van Lier, J J ^a   Van Heiningen, P N M ^a   Sunzel, M ^b  

^a PRA International USA   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin II receptor blocker; Candesartan; Candesartan cilexetil; Healthy volunteers; Intravenous, oral administration; Pharmacokinetics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; CARBON 14;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CARBON RADIOISOTOPES; CROSS-OVER STUDIES; HUMANS; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030722237     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Morimoto S, Ogihara T. TGV-116: a new angiotensin II type-I receptor antagonist. Cardiovasc Drug Rev 1994; 12: 153-164
2. Ogihara T et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV16. J Hypertens 1994; 12 (Suppl 9): S35-S38